You are here

Meeting Highlights

American College of Gastroenterology: 2006 Annual Scientific Meeting and Postgraduate Course

Walter Alexander
PDF version: 
Two biologic agents are featured: infliximab (Remicade), which is approved for the treatment of ulcerative colitis, and adalimumab (Humira), indicated for patients with Crohn’s disease.